A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Citadel Advisors LLC holds 23,700 shares of ABUS stock, worth $93,378. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,700
Previous 93,100 74.54%
Holding current value
$93,378
Previous $240,000 69.58%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$2.52 - $3.63 $4.66 Million - $6.72 Million
-1,850,929 Reduced 92.74%
144,875 $447,000
Q1 2024

May 15, 2024

BUY
$2.26 - $2.92 $139,771 - $180,590
61,846 Added 3.2%
1,995,804 $5.15 Million
Q4 2023

Feb 14, 2024

SELL
$1.69 - $2.54 $142,330 - $213,916
-84,219 Reduced 4.17%
1,933,958 $4.83 Million
Q3 2023

Nov 14, 2023

SELL
$1.9 - $2.27 $530,090 - $633,318
-278,995 Reduced 12.15%
2,018,177 $4.1 Million
Q2 2023

Aug 14, 2023

BUY
$2.24 - $3.06 $4.65 Million - $6.35 Million
2,076,034 Added 938.8%
2,297,172 $5.28 Million
Q1 2023

May 15, 2023

SELL
$2.23 - $3.1 $324,960 - $451,738
-145,722 Reduced 39.72%
221,138 $670,000
Q4 2022

Feb 14, 2023

BUY
$1.91 - $2.85 $342,082 - $510,437
179,101 Added 95.39%
366,860 $854,000
Q3 2022

Nov 14, 2022

BUY
$1.88 - $2.88 $198,163 - $303,569
105,406 Added 127.99%
187,759 $358,000
Q2 2022

Aug 15, 2022

SELL
$1.98 - $3.17 $554,451 - $887,682
-280,026 Reduced 77.27%
82,353 $223,000
Q1 2022

May 16, 2022

BUY
$2.42 - $3.98 $57,187 - $94,051
23,631 Added 6.98%
362,379 $1.08 Million
Q4 2021

Feb 14, 2022

SELL
$3.11 - $4.61 $6,611 - $9,800
-2,126 Reduced 0.62%
338,748 $1.32 Million
Q3 2021

Nov 15, 2021

BUY
$2.65 - $4.62 $609,348 - $1.06 Million
229,943 Added 207.28%
340,874 $1.46 Million
Q2 2021

Aug 16, 2021

SELL
$2.5 - $3.51 $1.46 Million - $2.05 Million
-585,412 Reduced 84.07%
110,931 $336,000
Q1 2021

May 17, 2021

BUY
$3.14 - $4.84 $1.88 Million - $2.89 Million
597,446 Added 604.11%
696,343 $2.32 Million
Q4 2020

Feb 16, 2021

BUY
$2.76 - $4.97 $79,297 - $142,793
28,731 Added 40.95%
98,897 $351,000
Q3 2020

Nov 16, 2020

SELL
$1.75 - $6.2 $2.24 Million - $7.94 Million
-1,280,189 Reduced 94.8%
70,166 $219,000
Q2 2020

Aug 14, 2020

SELL
$0.91 - $2.36 $1.03 Million - $2.66 Million
-1,127,764 Reduced 45.51%
1,350,355 $2.46 Million
Q1 2020

May 15, 2020

BUY
$1.01 - $3.42 $2.45 Million - $8.29 Million
2,423,126 Added 4406.24%
2,478,119 $2.5 Million
Q4 2019

Feb 14, 2020

BUY
$0.87 - $2.89 $37,439 - $124,368
43,034 Added 359.85%
54,993 $153,000
Q2 2019

Aug 14, 2019

SELL
$1.46 - $4.44 $3,308 - $10,061
-2,266 Reduced 15.93%
11,959 $25,000
Q1 2019

May 15, 2019

SELL
$3.41 - $4.57 $219,576 - $294,271
-64,392 Reduced 81.91%
14,225 $0
Q2 2018

Aug 10, 2018

BUY
$5.0 - $7.35 $69,100 - $101,577
13,820 Added 21.33%
78,617 $0
Q1 2018

May 11, 2018

BUY
$4.4 - $6.05 $158,316 - $217,685
35,981 Added 124.86%
64,797 $324,000
Q4 2017

Feb 09, 2018

BUY
$4.45 - $7.7 $128,231 - $221,883
28,816
28,816 $146,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $591M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.